Type 2 Diabetes Clinical Trial
— TIMEXOfficial title:
Hedonic and Homeostatic Appetite Control in Obesity and Type 2 Diabetes in the Context of Meal and Exercise Timing
The overall aim is to investigate effects of acute exercise on ad libitum energy intake and study whether this differs between morning and evening in individuals with overweight/obesity with or without type 2 diabetes (T2D). Furthermore, the aim is to examine the role of hedonic and homeostatic drivers of appetite control in obesity and T2D in the context of meal and exercise timing.
Status | Recruiting |
Enrollment | 58 |
Est. completion date | July 31, 2026 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Adults with overweight or obesity (BMI >25 kg/m2) with and without T2D - HbA1c =48 mmol/mol for people with T2D Exclusion Criteria: - Not able to eat ad libitum meal - Not able to perform the exercise bout - Daily smoking - For women: Pregnancy / planned pregnancy (within the study period) / lactating - Self-reported history of an eating disorder in the past 3 years - Self-reported weight change (>5 kg) within three months prior to inclusion - Treatment with antidepressants - Treatment with fast acting insulin, combination insulin products and sulfonylureas - Alcohol/drug abuse or in treatment with disulfiram (antabus) at time of inclusion - Uncontrolled medical issues including but not limited to cardiovascular pulmonary, rheumatologic, hematologic, oncologic, infectious, gastrointestinal, or psychiatric disease; diabetes or other endocrine disease; immunosuppression - Current treatment with medication which significantly affect appetite or energy balance (e.g., GLP-1 receptor agonists) - Bariatric surgery - Unable to understand the informed consent and the study procedures - Concomitant participation in intervention studies - Incapable of understanding Danish |
Country | Name | City | State |
---|---|---|---|
Denmark | Steno Diabetes Center Copenhagen | Herlev |
Lead Sponsor | Collaborator |
---|---|
Steno Diabetes Center Copenhagen | Novo Nordisk A/S, University of Leeds |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ad libitum energy intake (KJ) after exercise compared with rest | Food intake (KJ) is measured after meal completion, exercise compared with rest | Measured after meal consumption at t = 30 minutes | |
Secondary | Ad libitum energy intake (KJ) after exercise in the morning compared with evening | Assess whether energy intake during an ad libitum meal after exercise differs between morning and evening | Measured after meal consumption at t = 30 minutes | |
Secondary | Ad libitum energy intake (KJ) after rest in the morning compared with evening | Assess whether energy intake during an ad libitum meal after rest differs between morning and evening | Measured after meal consumption at t = 30 minutes | |
Secondary | Eating pace (KJ/min) | Energy intake relative to duration of meal consumption | Measured from start to finish of meal consumption at t = 15 minutes to end of meal, morning and evening, exercise and rest | |
Secondary | Glucose (mmol/L) | Concentrations of glucose | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Triglyceride (mmol/L) | Concentrations of triglyceride | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Total cholesterol (mmol/L) | Concentrations of total cholesterol | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | LDL cholesterol (mmol/L) | Concentrations of LDL cholesterol | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | HDL cholesterol (mmol/L) | Concentrations of HDL cholesterol | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | VLDL cholesterol (mmol/L) | Concentrations of VLDL cholesterol | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Free-Fatty Acids (mmol/L) | Concentrations of Free-Fatty Acids. | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Circulating metabolides (metabolomics) (g/mL) | Concentrations of circulating metabolides measured with metabolomic analysis | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Circulating lipids (lipidomics) (g/mL) | Concentrations of circulating lipids measured with lipidomic analysis | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Circulating proteins (proteomics) (g/mL) | Concentrations of circulating proteins measured with proteomic analysis | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Insulin (pmol/L) | Concentrations of insulin | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Glucagon (pmol/L) | Concentrations of glucagon | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Total ghrelin (pmol/L) | Concentrations of total ghrelin | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Acylated ghrelin (pmol/L) | Concentrations of acylated ghrelin | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Glucagon-Like Peptide-1 (GLP-1) (pmol/L) | Concentrations of Glucagon-Like Peptide-1 (GLP-1) | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Glucose-Dependent Insulinotropic polypeptide (GIP) (pmol/L) | Concentrations of Glucose-Dependent Insulinotropic polypeptide (GIP) | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | C-peptide (pmol/L) | Concentrations of C-peptide | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Peptide YY (PYY) (pmol/L) | Concentrations of Peptide YY (PYY) | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Peptide YY (PYY) 3-36 (pmol/L) | Concentrations of Peptide YY (PYY) 3-36 | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Fibroblast Growth Factor 21 (FGF-21) (pmol/L) | Concentrations of Fibroblast Growth Factor 21 (FGF-21) | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Leptin (pmol/L) | Concentrations of Leptin | Fasting (t = -60 minutes), and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Growth Differentiation Factor 15 (GDF-15) (pmol/L) | Concentrations of Growth Differentiation Factor 15 (GDF-15) | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Cholecystokinin (CCK) (pmol/L) | Concentrations of Cholecystokinin (CCK) | Fasting (t = -60 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Pancreatic polypeptide (PP) (pmol/L) | Concentrations of Pancreatic polypeptide (PP) | Fasting (t = -60 minutes), and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | C-reactive protein (CRP) (pmol(L) | Concentrations of C-reactive protein (CRP) | Fasting (t = -60 minutes), and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Food choice | Food choice of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the SBFPT. Food choice is determined based on frequency of selection made within each food category. The scores range from 0-48 i.e. 0 = foods within a specific food category have not been selected at all to 48 = foods within a specific food category have been selected 48 times. | Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest | |
Secondary | Attention | Measured using eye tracking in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire.
Includes the following parameters: Gaze: Time spent (ms and %) and revisits (n); and fixations: Time to first fixation (ms), time spent (ms and %), fixation count (n), first fixation duration (ms), average fixation duration (ms). Distance to screen (mm), and gaze direction bias (ratio) which is calculated as the number of trials in which the first fixation was directed to a food image as a proportion to all trials. A bias score ?0.5 indicates attention towards one food image, a bias score equal to 0.5 indicates no bias, and a bias score <0.5 indicates attention towards the other food images. |
Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest | |
Secondary | Reaction time (ms) | Reaction time during forced food choice of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. | Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest | |
Secondary | Explicit liking | Explicit liking of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the SBFPT. Explicit liking is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how pleasant would it be to taste this food right now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale). | Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest | |
Secondary | Implicit wanting | Implicit wanting of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the SBFPT. Implicit wanting is assessed based on food choice and response time for selected and non-selected food items as well as mean response time (a frequency-weighted algorithm).
In this frequency-weighted algorithm a positive score indicates a more rapid preference for a food type over another food type and a negative score indicates the opposite. A score of zero indicates that food types are equally preferred. The frequency weighted algorithm is used so the implicit wanting score is influenced by both selection (positively contributing to the score) and non-selection (negatively contributing to the score) of food type. Scores for implicit wanting typically range from -100-100 (due to reaction time there is no fixed min-max value) |
Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest | |
Secondary | Explicit wanting | Explicit wanting of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the SBFPT. Explicit wanting is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how much do you want some of this food now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale). | Measured before exercise/rest (t = -60 minutes) and after meal consumption (t= 30 minutes), morning and evening, exercise and rest | |
Secondary | Subjective appetite | Rated using visual analogue scales and includes sensations of: Hunger, fullness, satiety, prospective food consumption, wellbeing, nausea, thirst, desire to eat meat, salty, and sweet. The scale range is 0-100 and each end represent the extremes e.g. hunger rating: "I am not hungry at all" to "I have never been this hungry before". | Fasting (t = -60, 0 minutes) and at t = 0, 15, 30, 45, 60 minutes, morning and evening, exercise and rest | |
Secondary | Energy intake (KJ) | Assessed from diet records | Registered 24 hours after the test days, morning and evening, exercise and rest | |
Secondary | Borg RPE | Subjective rating of the level of exertion during exercise is collected through the Borg Rating of Percieved Exertion (RPE) at baseline and post exercise, and compared between visits. | Measured after exercise (t = 0 minutes) , morning and evening |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |